Answers are grounded in this paper and cite their sources.
Olaparib showed efficacy in different cancer types harboring somatic or germline mutations in the BRCA1/2 genes but not in ATM and CHEK2. Patients with any cancer type harboring BRCA1/2 mutations should have access to olaparib.
No takes yet. Share an insight, caveat, or question.
Joris et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: